Patents Assigned to CMG Pharmaceutical CO., LTD>
-
Publication number: 20230348423Abstract: Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER, and/or c-Met is inhibited, the compound or pharmaceutically acceptable salt thereof can re-sensitize cancer cells, such as non-small cell lung cancer cells, that have grown resistant to an anti-cancer agent.Type: ApplicationFiled: January 30, 2023Publication date: November 2, 2023Applicant: CMG Pharmaceutical Co., Ltd.Inventors: Jin Sung KIM, Young Sang KIM, Sungmoo KIM, Ju Hui JEONG, Hyun Sook AN, Soojeong KIM
-
Publication number: 20230257364Abstract: Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER, and/or c-Met is inhibited, the compound or pharmaceutically acceptable salt thereof can re-sensitize cancer cells, such as non-small cell lung cancer cells, that have grown resistant to an anti-cancer agent.Type: ApplicationFiled: January 30, 2023Publication date: August 17, 2023Applicants: CMG Pharmaceutical Co., Ltd., Sungkwang Medical FoundationInventors: Jin Sung KIM, Sungmoo KIM, Ju Hui JEONG, Hyun Sook AN, Soojeong KIM
-
Patent number: 11370758Abstract: Provided is an inhibitor of an indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) of formula (I) or a pharmaceutically acceptable salt thereof: in which W1, W2, W3, and W4, X, Y, Z1, Z2, and R1-7 are described herein. Further provided is a method of treating or preventing a IDO and/or TDO-mediated disease using an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 22, 2019Date of Patent: June 28, 2022Assignees: CMG PHARMACEUTICAL CO., LTD., SUNGKWANG MEDICAL FOUNDATIONInventors: Hong Jae Jeon, Chan Kim, Na Keum Lee, Jin Sung Kim, Hye Sun Jeon, Young Eun Kwon, Ju Hui Jeong
-
Publication number: 20190292150Abstract: Provided is an inhibitor of an indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) of formula (I) or a pharmaceutically acceptable salt thereof: in which W1, W2, W3, and W4, X, Y, Z1, Z2, and R1-7 are described herein. Further provided is a method of treating or preventing a IDO and/or TDO-mediated disease using an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 22, 2019Publication date: September 26, 2019Applicants: CMG PHARMACEUTICAL CO., LTD., SUNGKWANG MEDICAL FOUNDATIONInventors: Hong Jae JEON, Chan KIM, Na Keum LEE, Jin Sung KIM, Hye Sun JEON, Young Eun KWON, Ju Hui JEONG
-
Patent number: 9701681Abstract: The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases.Type: GrantFiled: December 14, 2015Date of Patent: July 11, 2017Assignees: CMG PHARMACEUTICAL CO., LTD., HANDOK INC.Inventors: Moonsoo Kim, Chaewoon Lee, Gilnam Lee, Cheol Hwan Yoon, Jeongbeob Seo, Je Hak Kim, MinWoo Lee, Hankyul Jeong, Hyang Choi, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Hye Kyoung Kim, Jae Il Lee, Misoon Kim, Soongyu Choi
-
Patent number: 9694008Abstract: The present invention relates to an orally fast dissolving film formulation including aripiprazole. The orally fast dissolving film formulation includes aripiprazole or a pharmaceutically acceptable salt thereof and an organic acid. The orally fast dissolving film formulation has a pH in the range of 4.7 to 6.0. The orally fast dissolving film formulation may further include a film base polymer. The orally fast dissolving film formulation has a high dissolution rate, causes no risk of damage to oral tissues, masks a bitter taste of aripiprazole, and gives a good feeling upon taking.Type: GrantFiled: August 7, 2013Date of Patent: July 4, 2017Assignee: CMG Pharmaceutical Co., LTD.Inventors: Yong Soo Kim, Jun Ho Shin
-
Patent number: 9617261Abstract: The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans.Type: GrantFiled: December 21, 2015Date of Patent: April 11, 2017Assignee: CMG PHARMACEUTICAL CO., LTD.Inventors: Gilnam Lee, Hye Sun Jeon, Ki Joon Jeon, Chul Yun Rhim, Jin Sung Kim, Jeongbeob Seo, Suk Young Cho, Choung Soo Kim, Jung Shin Lee, Eun Kyung Choi, Jung Jin Hwang, Bongcheol Kim
-
Patent number: 9422298Abstract: The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3? OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.Type: GrantFiled: February 13, 2015Date of Patent: August 23, 2016Assignees: CMG Pharmaceutical Co., Ltd., Sung Kwang Medical FoundationInventors: Gilnam Lee, Chul Soo Lim, Han Won Cho, Jeongbeob Seo, Albert C. Gyorkos, Suk Young Cho, Eun Kyung Choi, Choung Soo Kim, Jung Jin Hwang, Jin Sung Kim, Hee Jung An, Yong Wha Moon
-
Publication number: 20150196558Abstract: The present invention relates to an orally fast dissolving film formulation including aripiprazole. The orally fast dissolving film formulation includes aripiprazole or a pharmaceutically acceptable salt thereof and an organic acid. The orally fast dissolving film formulation has a pH in the range of 4.7 to 6.0. The orally fast dissolving film formulation may further include a film base polymer. The orally fast dissolving film formulation has a high dissolution rate, causes no risk of damage to oral tissues, masks a bitter taste of aripiprazole, and gives a good feeling upon taking.Type: ApplicationFiled: August 7, 2013Publication date: July 16, 2015Applicant: CMG Pharmaceutical CO., LTD>Inventors: Yong Soo Kim, Jun Ho Shi